Skip to Content

What type of drug is Lumoxiti?

Answers (1)

Official Answer by Drugs.com 15 Oct 2018

Lumoxiti (moxetumomab pasudotox-tdfk) is a first-in-class treatment for patients with hairy cell leukemia (HCL), a blood cancer that results in excessive production of B cells, a type of white blood cell that appears "hairy" under microscopic examination. It is approved for the treatment of relapsed or refractory HCL in patients who have received at least two prior lines of therapy.

Lumoxiti is classified as an injectable anti-CD22 (antibody-drug conjugate against CD-22) recombinant immunotoxin. Immunotoxin biologics like Lumoxiti are cancer agents that deliver targeted drug therapy to kill cancer cells. CD22 is a protein that is found in higher amounts in HCL cells compared to healthy B cells, making it a reasonable target for drug treatment. Lumoxiti is from manufacturer AstraZeneca.

Besponsa (inotuzumab ozogamicin) injection is also CD22-directed antibody-drug conjugate, approved for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). Besponsa is manufactured by Pfizer.

Drugs.com free discount card

Further Information

Search for questions

Still looking for answers? Try searching for what you seek or ask your own question.

Frequently Asked Questions

What type of drug is Motegrity?

Updated 19 days ago 1 answerFAQ by Drugs.com

What disease is Elzonris (tagraxofusp-erzs) used to treat?

Updated 16 days ago 1 answerFAQ by Drugs.com

How do you use the ProAir Digihaler?

Updated 16 days ago 1 answerFAQ by Drugs.com

How many biosimilars have been approved in the United States?

Updated 15 days ago 1 answerFAQ by Drugs.com